Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sandostatin LAR plus cabergoline, with optional switch to Sandostatin LAR plus pegvisomant, in partially responsive acromegaly
2005-002919-24Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2006
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of octreotide, cabergoline and pegvisomant in acromegaly (2 arms), sponsored by Novartis. Primary endpoints: Primary biochemical response and Ability of Sandostatin LAR + cabergoline to reduce GH and IGF-I. Started Jun 2006; status: completed.
02
Drugs
octreotidecabergolinepegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2005-002919-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002919-24.